Cargando…
Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA
Liquid biopsy is a valuable precision oncology tool that is increasingly used as a non-invasive approach to identify biomarkers, detect resistance mutations, monitor disease burden, and identify early recurrence. The Tempus xF liquid biopsy assay is a 105-gene, hybrid-capture, next-generation sequen...
Autores principales: | Finkle, Justin D., Boulos, Hala, Driessen, Terri M., Lo, Christine, Blidner, Richard A., Hafez, Ashraf, Khan, Aly A., Lozac’hmeur, Ariane, McKinnon, Kelly E., Perera, Jason, Zhu, Wei, Dowlati, Afshin, White, Kevin P., Tell, Robert, Beaubier, Nike |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253837/ https://www.ncbi.nlm.nih.gov/pubmed/34215841 http://dx.doi.org/10.1038/s41698-021-00202-2 |
Ejemplares similares
-
Longitudinal Shifts of Solid Tumor and Liquid Biopsy Sequencing Concordance in Metastatic Breast Cancer
por: Liu, Minetta C., et al.
Publicado: (2022) -
Clinical validation of the tempus xT next-generation targeted oncology sequencing assay
por: Beaubier, Nike, et al.
Publicado: (2019) -
The Role of Liquid-crystalline Structures in the Morphogenesis of Animal Fibers
por: McKinnon, A John, et al.
Publicado: (2010) -
Tumor Mutational Burden From Tumor-Only Sequencing Compared With Germline Subtraction From Paired Tumor and Normal Specimens
por: Parikh, Kaushal, et al.
Publicado: (2020) -
Current advances of liquid biopsies in prostate cancer: Molecular biomarkers
por: Alahdal, Murad, et al.
Publicado: (2023)